This trial is evaluating whether Leuprolide acetate will improve 2 primary outcomes and 3 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to 15 months.
This trial requires 42 total participants across 4 different treatment groups
This trial involves 4 different treatments. Leuprolide Acetate is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Although the cure rate is low, patients can expect to be cured of prostate cancer, if they can be recognized early. However, many prostate cancer patients are diagnosed at later stages. If prostate cancer is diagnosed late it more often results in death, compared to early diagnosed patients. On the basis of these results, the cure rate is very small for prostate cancer, but it shows a large potential of improvement through early diagnosis, and therefore high cure rates could be reached with further optimization of screening methods and treatment options." - Anonymous Online Contributor
"There have been significant increases in prostate cancer diagnoses in the United States, although the number of people diagnosed is relatively low compared with other European countries. A rising trend, which might be attributed to improved detection, has been evident in the past 10 years." - Anonymous Online Contributor
"The symptoms of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) are often not present until a late stage. Symptoms are more important determinants of quality of life than cancer related factors.\n" - Anonymous Online Contributor
"The treatments for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) are largely dependent on the characteristics of cancer: its severity and the presence of metastasis (trend of less aggressive and better prognosis cancers, respectively). They usually include surgery, radiation therapy or targeted therapy. The most common hormonal therapy, as well as some immunotherapy and chemotherapy. Other solutions include surgical removal of the prostate and the use of a combination of androgen deprivation therapy and chemotherapy." - Anonymous Online Contributor
"Although most cancers are not caused by a single factor, some cancers have an identifiable set of causative factors. Understanding these relationships can help prevent or reduce the likelihood of developing prostate cancer. And with the appropriate amount and duration of exposure to the causative agent, it can also prevent or reduce the risk of developing prostate cancer. These factors include lifestyle, genetic and environmental factors, including diet, hormones such as estrogens and growth factors such as testosterone. The role of chemical, occupational, or environmental toxins or irradiation in prostate cancer is unclear and needs further investigation." - Anonymous Online Contributor
"Testicular masses on ultrasound are the most common ultrasound findings of prostate cancer in the absence of symptoms. In those with symptoms, digital rectal examination may uncover palpable masses." - Anonymous Online Contributor
"The number of men with at least one risk factor increases very quickly from age 50 to 60 or 70. Based on data from one epidemiological study the probability of developing prostate cancer for a man at age 70 is 6.3%." - Anonymous Online Contributor
"Findings from a recent study from the trial and the publications of this study in regards to the leuprolide acetate preparations, are in concordance with previous publications. Despite the lack of data from the aforementioned publications, in regards to the occurrence of any serious side effects leuprolide acetate might possess, it is unlikely that any other dosage could be more advantageous as a treatment option for prostate cancer than the dosage of the present study. Therefore, the authors conclude that the result of the study is a milestone supporting the indication of leuprolide acetate and underlining the effectiveness of the preparation." - Anonymous Online Contributor
"Men who have a Gleason sum of > 8 or who have PSA > 1.0 ng/mL may be at high risk for metastases at presentation. Patients with a Gleason sum of 4, PSA between 0.1 and 1.0 ng/mL, and/or a T(a)/T(b)> 0.5 are candidates for more aggressive management strategies." - Anonymous Online Contributor
"Age, smoking, race, total body testosterone, and a history of prostate disease among men with prostate cancer are associated with the development of an aggressive phenotype. The study suggests that the prostate gland may be the target for initiation or amplification of aggressive behavior in men with prostate cancer, particularly in younger patients who have a history of high serum testosterone. Additional studies are indicated of the impact of testosterone therapy in the genesis of progressive prostate cancers." - Anonymous Online Contributor
"Recent findings of this study are of great importance to the urological community, being the results, from both centers, concordant and support the notion that LA is more effective than placebo in the treatment of LUTS as one of its major indications. Moreover, the findings highlight LA as a suitable and effective treatment choice in a cohort of patients, who have never received LA therapy before, but they will soon probably start it. With LA as an important therapeutic option it is crucial to make known, in clinical practice, the evidence in support of its effectiveness." - Anonymous Online Contributor
"A large number of new research reports have appeared in both the medical literature and on the web. This is in tandem with an overall increase in the number of prostate cancer cases diagnosed worldwide. In addition to improving the quality of care of patients with prostate cancer, this body of new information promotes the development of improved diagnostic and interventional techniques for this disease, and warrants a need for a greater international collaboration to optimize these advances." - Anonymous Online Contributor